Growth hormone release factor (TH9507) reduces central fat adiposity
4 April 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Conference reports
Further insight into risk and management of cardiovascular disease (CVD) from D:A:D cohort: no additional benefit of metabolic syndrome diagnosis; new HIV-specific CVD risk equations; increasing uptake of lipid lowering drugs but low smoking cessation
4 April 2007. Related: Conference reports, Side effects.
Pregnancy outcomes in the DART trial
4 April 2007. Related: Conference reports, Pregnancy.
12 month response to HAART in women following exposure to prevention of mother to child transmission regimens
4 April 2007. Related: Conference reports, Pregnancy.
Unexpectedly high rate of K65R mutation in patients failing first-line d4T-containing regimens in Thailand
4 April 2007. Related: Conference reports, Drug resistance.
Sexual transmission of HCV in Brighton reported in HIV positive and HIV negative MSM
4 April 2007. Related: Conference reports, Hepatitis coinfection.
Hepatitis B drug entecavir reported to have anti-HIV viral activity in three patients
4 April 2007. Related: Conference reports, Hepatitis coinfection.
High 6-month rate of PML survival with aggressive use of 5-drug T-20-based ARV regimen
4 April 2007. Related: Conference reports, Coinfections and complications.
Increased anal HPV levels in HV-positive smokers
4 April 2007. Related: Conference reports, Cancer and HIV.
Clade-B HIV-1 infection in Haiti predates global subtype-B virus
4 April 2007. Related: Conference reports.
Drug interactions and pharmacokinetic studies: CROI 2007
4 April 2007. Related: Conference reports, PK and drug interactions.
BHIVA Autumn conference, 13-14 October 2006, London
8 December 2006. Related: Conference reports.
Causes of death in the UK: results from BHIVA audit
7 December 2006. Related: Conference reports.
8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow
7 December 2006. Related: Conference reports.
Higher doses of ribavirin increases response rate to HCV treatment in coinfected patients: results from PRESCO study
6 December 2006. Related: Conference reports, Hepatitis coinfection.
NNRTI levels high in HCV co-Infected patients with cirrhosis
6 December 2006. Related: Conference reports, Hepatitis coinfection.
Viral load blips in children from the CHIPS cohort
6 December 2006. Related: Conference reports.
Multi-drug resistance in vertically infected children
6 December 2006. Related: Conference reports, Paediatric care, Drug resistance.
Wide disparity in switch to second-line therapy among children in CHIPS cohort
6 December 2006. Related: Conference reports, Paediatric care.
Explanation for failure of TMC-125 (etravirine) in TMC227 study
6 December 2006. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r: interim results from the Gemini study
6 December 2006. Related: Conference reports, Antiretrovirals.
d4T associated with significantly increased risk of type-2 diabetes mellitus
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Drug interactions with darunavir (TMC-114)
6 December 2006. Related: Conference reports, PK and drug interactions.
Drug interactions with etravirine (TMC-125)
6 December 2006. Related: Conference reports, PK and drug interactions.
Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Community meeting on criminalisation of HIV transmission: jailing people for passing on HIV may threaten public health
6 December 2006. Related: Conference reports.
8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 23-26 September 2006, San Francisco
16 October 2006. Related: Conference reports.
The role of the metabolic syndrome in HIV
15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Leptin reduces visceral abdominal tissue (VAT) without reducing limb fat
8 October 2006. Related: Conference reports.
Adipose tissue morphology improved after treatment discontinuation
8 October 2006. Related: Conference reports.
Incidence of lipodystrophy in Rwanda
8 October 2006. Related: Conference reports.
46th Interscience Conference on Antiretroviral Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco
7 October 2006. Related: Conference reports.
MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results
7 October 2006. Related: Conference reports, Drug resistance.
Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients
7 October 2006. Related: Conference reports, Antiretrovirals.
Cell studies predict cross-resistance among integrase inhibitors
7 October 2006. Related: Conference reports, Drug resistance.
HIV may use different coreceptors in blood and brain
7 October 2006. Related: Conference reports, Basic science and immunology.
Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives
7 October 2006. Related: Conference reports, PK and drug interactions.
NRTI elvucitabine active against HIV in a 7-day monotherapy study
7 October 2006. Related: Conference reports, Antiretrovirals.
Efavirenz/tenofovir fails as 2-drug maintenance regimen
7 October 2006. Related: Conference reports, Antiretrovirals.
Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees
7 October 2006. Related: Conference reports, Hepatitis coinfection.
Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London
7 October 2006. Related: Conference reports, Drug resistance.
Further reports from XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada
7 October 2006. Related: Conference reports.
Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV positive women in Lusaka, Zambia
7 October 2006. Related: Conference reports, Women's health, Cancer and HIV.
Effect of herpes simplex therapy on genital and plasma HIV viral load
7 October 2006. Related: Conference reports, Women's health.
Maternal health and prevention of mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
18-month effectiveness of short-course perinatal antiretroviral regimens combined to infant-feeding interventions for PMTCT in DITRAME PLUS ANRS 1201/1202 2001-2005
7 October 2006. Related: Conference reports, Pregnancy.
HIV prevalence rates amongst 6 week old infants in South Africa: the case for universal screening at immunisation clinics
7 October 2006. Related: Conference reports, Pregnancy.
Maternal illness during pregnancy is associated with In utero mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
Extensively drug resistant TB (XTB) in South Africa
7 October 2006. Related: Conference reports, TB coinfection.
XVI International AIDS Conference, Toronto, Canada. 13-18 August 2006
15 September 2006. Related: Conference reports.
Enough is enough: South African activists demand: fire Manto
10 September 2006. Related: Conference reports, Treatment access.
Treatment access: more optimistic results from scale up programmes
10 September 2006. Related: Conference reports, Treatment access.
Integrase inhibitor MK-0518: early results show greater early potency than efavirenz
10 September 2006. Related: Conference reports, Antiretrovirals.
Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect
10 September 2006. Related: Conference reports, Antiretrovirals.
Vicriviroc 24-week results in triple-class experienced R5-tropic patients
10 September 2006. Related: Conference reports, Antiretrovirals.
Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355
9 September 2006. Related: Conference reports, Antiretrovirals.
New data on darunavir (TMC-114)
9 September 2006. Related: Conference reports, Antiretrovirals.
Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance
9 September 2006. Related: Conference reports, Antiretrovirals.
Atazanavir/r monotherapy and CNS penetration
9 September 2006. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks
9 September 2006. Related: Conference reports, Antiretrovirals.
Children face a serious service delivery gap: paediatric studies in Toronto
9 September 2006. Related: Conference reports, Paediatric care.